Key Segments:
By Disease Type
-
Crohn's Disease
-
Ulcerative Colitis
By Drug Class
-
TNF Inhibitors
-
Aminosalicylates
-
Corticosteroids
-
Immunomodulators
-
JAK Inhibitors
-
Others
By Route of Administration
-
Injectable
-
Oral
By Distribution Channel
-
Hospital Pharmacy
-
Retail Pharmacy
-
Online Pharmacy
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include AbbVie Inc., Johnson & Johnson, Takeda Pharmaceutical Company Limited, Pfizer Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, and F. Hoffmann-La Roche Ltd, among other global immunology drug developers.
Expansion of the biosimilar market and advances in personalized medicine that enhance targeted treatment strategies represent the primary opportunities.
Growth is primarily driven by the increasing global prevalence of inflammatory bowel disease combined with expansion of advanced immunology drugs and improved disease monitoring.
By Drug Class, TNF Inhibitors dominated the market with approximately 35.60% share in 2025, reflecting strong, long-established clinical efficacy and high physician familiarity.
North America dominated the market with approximately 52.60% share in 2025, supported by high disease prevalence, well-established healthcare infrastructure, and broad biologic therapy reimbursement coverage.
